Crossmark

Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial

Crossref DOI link: https://doi.org/10.1007/s12325-022-02206-1

Published Online: 2022-06-30

Published Print: 2022-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Jingxin

Hui, Ai-Min https://orcid.org/0000-0002-3688-1570
Zhang, Xiang

Ge, Lei

Qiu, Yuanzheng

Tang, Rong

Ye, Huayue

Wang, Xiyuan

Lin, Mei

Zhu, Zhongkui

Zheng, Jianfei

Qiu, Jingjun

Lagkadinou, Eleni

Shpyro, Svetlana

Ozhelvaci, Orkun

Türeci, Özlem

Khondker, Zakaria

Yin, Wanrong

Shishkova, Yoana

Jia, Siyue

Pan, Hongxing

Peng, Fuzhong

Ma, Zhilong

Wu, Zhenggang

Guo, Xiling

Shi, Yunfeng

Muik, Alexander

Şahin, Uğur

Zhu, Li https://orcid.org/0000-0002-6804-5235
Zhu, Fengcai https://orcid.org/0000-0002-1644-0006
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04523571 at ClinicalTrials.gov

Documents that mention this clinical trial

Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial
https://doi.org/10.1007/s12325-022-02206-1
Funding

Funding for this research was provided by:

BioNTech

Shanghai Fosun Pharmaceutical
License Information

Text and Data Mining valid from 2022-06-30

Version of Record valid from 2022-06-30
More Information

Article History

Received: 6 April 2022

Accepted: 20 May 2022

First Online: 30 June 2022

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below